Spectrum Antimicrobials, Inc.

PETALUMA, CA · Founded 2016 · Biotech · Private

precision chemistry antimicrobial compounds

Claim this profile

Follows are private to you and power your alerts

Updated · spectrumantimicrobials.com

Sector
Biotech
Headquarters
PETALUMA, CA
Founded
2016
Latest Form D
$3.9M, Sep 2024
Total capital
$4.7M
Federal grants
None on recordNo awards found in SBIR/STTR, NIH, NSF or DoD records.
Private capital raised
$4.7M
2 Form D · last Sep 2024
25 months since last filing
Federal contracts
None on recordNo federal contract awards found.
Granted patents
None on recordNo USPTO grants. Applications publish after 18 months.

Capital timeline

20202021202220232024FEDERAL ↑EQUITY ↓Cumulative $4.7M1st Form D$890K2nd Form D$3.9M
20202021202220232024FEDERAL ↑EQUITY ↓Cumulative $4.7M1st Form D$890K2nd Form D$3.9M

Latest events

  • Private capital raisedForm D · SEC · 2nd filing$3.9M
  • Private capital raisedForm D · SEC · 1st filing$890K

Node area is scaled to amount. Form D reports securities sold, which can differ from an announced round; filings are numbered in the order they were made.

Founders and team

From SEC Form D filings
  • David Henry AllieDirectorNamed in SEC Form D filings
  • Hojabr AlimiExecutive Officer, Director, PromoterNamed in SEC Form D filings
  • Jerry Henry StonemetzExecutive OfficerNamed in SEC Form D filings
  • Kate LewisDirectorNamed in SEC Form D filings
  • Richard ZimmerExecutive OfficerNamed in SEC Form D filings
  • Ronald H. CarliDirectorNamed in SEC Form D filings
Show all 11 people
  • Sameer HarishExecutive OfficerNamed in SEC Form D filings
  • Steven Henry SolferinoDirectorNamed in SEC Form D filings
  • Tchekanova BanafshehExecutive OfficerNamed in SEC Form D filings
  • William H. WatsonExecutive Officer, Director, PromoterNamed in SEC Form D filings
  • William Henry Watson IIIExecutive Officer, Director, PromoterNamed in SEC Form D filings

What it has protected

No granted patents are on record.

USPTO usually publishes applications 18 months after filing, so recent applications may not be visible yet. Patents assigned under a different entity name won’t match.

Checked: USPTO granted patents and published applications · Oct 23, 2026

  • OPAL THERAPEUTICS INCSimilar federal contract value in Biotech · null in contracts
  • GlycomineSimilar federal contract value in Biotech · null in contracts
  • Glyscend IncSimilar federal contract value in Biotech · null in contracts
  • Lipidio Pharmaceuticals Inc.Similar federal contract value in Biotech · null in contracts
  • IO THERAPEUTICS, INC.Similar federal contract value in Biotech · null in contracts
  • Hanimune Therapeutics IncSimilar federal contract value in Biotech · null in contracts

Regulatory activity · Biotech

Sector-level, not company-level

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.

Sources

Federal grants from SBIR/STTR, NIH, NSF and DoD records. Federal contracts from USAspending.gov. Private capital from SEC Form D. Patents from USPTO. Publications from OpenAlex. Regulatory activity from the Federal Register. Press matched on company name.

How to read this page

Figures show associations in public records, not causes or predictions. Nothing here is investment advice. An em-dash means no record was found under this company's name, not that none exists.

Data freshness

SEC Form D filings through . SBIR and STTR awards through .